Moderna, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bearish -45

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better ...

Company update Earnings report AI-generated analysis

πŸ“‰ Moderna's FY 2025 revenue dropped roughly 39.2% to nearly $1.9 billion as demand for COVID-19 products tapered.

πŸ’Έ Moderna reported a net loss of approximately $2.8 billion in FY 2025 with negative free cash flow of nearly $2.1 billion.

πŸ“ˆ Vertex Pharmaceuticals achieved revenue growth of 9.6% to reach close to $12.1 billion in FY 2025.

πŸ’° Vertex posted net income of nearly $4.0 billion and generated $3.2 billion in free cash flow during FY 2025.

βš–οΈ Moderna faces intense competition from established giants like Pfizer, Sanofi, and GSK in the vaccine market.

⚠️ Moderna is involved in a significant legal risk involving a $950 million settlement with Arbutus Biopharma regarding intellectual property.

πŸ₯ Vertex carries revenue concentration risk as its business is heavily dependent on its cystic fibrosis portfolio.

🧬 Vertex faces clinical development risks illustrated by the recent discontinuation of its VX-264 program for diabetes.

πŸ“‰ Moderna reported a significant net loss of $1.34 billion in Q1 2026, continuing its financial transition challenges.

πŸš€ Vertex management raised its full-year outlook in Q2 2026 while expanding its pipeline beyond cystic fibrosis.

Bullish Signals
  • Moderna maintains a global manufacturing footprint and operates in the biotech landscape with a platform technology capable of being retooled for almost any disease.
  • The company recently partnered with Recordati to advance new therapeutics, indicating ongoing strategic collaboration efforts.
Risk Factors
  • Moderna's FY 2025 revenue declined by roughly 39.2% compared to the prior year due to tapering demand for COVID-19 products.
  • The company reported a net loss of approximately $2.8 billion in FY 2025, resulting in a negative net margin of 145.2%.
  • Moderna experienced negative free cash flow of nearly $2.1 billion during FY 2025 after paying for capital expenditures.
  • The company faces intense competition from established giants like Pfizer, Sanofi, and GSK in the vaccine market.
  • Moderna is involved in a prominent legal risk including a $950 million settlement with Arbutus Biopharma regarding intellectual property.
  • The company reported a significant net loss of $1.34 billion in Q1 2026, highlighting continued financial pressure.
Full Analysis
The article compares Moderna (MRNA) and Vertex Pharmaceuticals (VRTX), noting that while Moderna pioneered mRNA vaccines, it faces significant financial headwinds as demand for its COVID-19 products tapers. In fiscal year 2025, Moderna's revenue declined by approximately 39.2% to nearly $1.9 billion, resulting in a net loss of roughly $2.8 billion and negative free cash flow of $2.1 billion. In contrast, Vertex Pharmaceuticals is highlighted as a profitable leader in cystic fibrosis treatments with revenue growing 9.6% to $12.1 billion in FY 2025. The company posted net income of nearly $4.0 billion and generated $3.2 billion in free cash flow, maintaining a strong balance sheet with low debt relative to equity. Moderna is described as playing a longer game to prove its platform works across various diseases, but it currently struggles with intense competition from giants like Pfizer and Sanofi, plus legal risks including a $950 million settlement. Vertex faces revenue concentration risk in cystic fibrosis and clinical development risks, such as the discontinuation of its VX-264 diabetes program, but is viewed as delivering immediate value. The author concludes that Vertex is the preferred choice for investors seeking current profitability and cash generation, whereas Moderna represents a higher-risk, longer-term opportunity dependent on successfully transitioning its portfolio beyond infectious disease vaccines.